Regenxbio (RGNX) Accumulated Expenses (2014 - 2025)

Regenxbio's Accumulated Expenses history runs 12 years deep, the most recent figure standing at $38.4 million for Q4 2025.

• On a quarterly basis, Accumulated Expenses rose 0.84% year-over-year to $38.4 million in Q4 2025; TTM through Dec 2025 was $38.4 million, a 0.84% increase from a year earlier, with the FY2025 full-year figure at $38.4 million, up 0.84% from the prior year.
• Accumulated Expenses held at $38.4 million in Q4 2025 per RGNX's latest filing, from $38.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $76.1 million in Q4 2021 and bottomed at $8.0 million in Q1 2021.
• The 5-year median for Accumulated Expenses is $40.4 million (2024), against an average of $37.6 million.
• Across the five-year window, Accumulated Expenses jumped 507.57% in 2022 and tumbled 74.5% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $76.1 million in 2021, then plunged by 38.52% to $46.8 million in 2022, then rose by 6.22% to $49.7 million in 2023, then dropped by 23.41% to $38.1 million in 2024, then gained by 0.84% to $38.4 million in 2025.
• Per Business Quant, the three latest RGNX Accumulated Expenses figures stand at $38.4 million (Q4 2025), $38.3 million (Q3 2025), and $35.6 million (Q2 2025).